Pharmacoeconomics of Alzheimer's disease

Jacquelyn Dinusson, David S Knopman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND - Alzheimer's disease (AD) is the most common form of dementia, comprising an estimated 60 to 80% of the dementing illnesses. As a result of increasing life expectancy and the rising incidence of dementia with advancing age, dementia is a major public health concern. The costs of treatment for AD in the United States rank it among major diseases, but its true costs are not well understood. Pharmacological treatment for AD has been available only in the past 7 years, and much needs to be learned about the current and potential benefits of AD treatment. REVIEW SUMMARY - The costs of caring for patients with AD can be divided into two categories: informal and formal. Informal care is largely provided by family caregivers. The costs associated with informal care involve the time spent in caregiving that constitutes lost opportunities for paid employment. Formal care includes acute medical services as well as day care, respite care, and especially long-term care. These generate what are referred to as formal costs, which are definitely higher for patients with AD than for other comparably aged patients. The introduction of cholinesterase inhibitors to treat AD has raised questions about their economic costs and benefits. Although virtually all clinical trials of anti-AD drugs are of short duration, economic modeling has made it possible to gain some insight into the economic benefits of anti- AD drugs over a longer time period. Four studies that describe economic costs and benefits of anti-AD therapy are reviewed. Because of the uncertainty about the duration and size of clinical effects of cholinesterase inhibitors, the estimates of costs and benefits span a range from cost-saving to expensive. Varying estimates also arise for the impact of anti-AD drugs on formal versus informal costs. If anti-AD therapies were to be shown to reduce formal costs such as nursing home placement, the impact of pharmacological intervention in AD could be dramatic. Economic modeling shows, however, that anti-AD drugs need to reduce informal costs to achieve more sizable economic impact. CONCLUSIONS - Given the efficacy of cholinesterase inhibitors and the current data on the duration of their effects, the estimated economic benefits of this class of drugs are modest. Developing economic models depict what order of magnitude of drug effects are necessary before substantial economic benefits could possibly occur.

Original languageEnglish (US)
Pages (from-to)116-125
Number of pages10
JournalNeurologist
Volume6
Issue number2
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Alzheimer Disease
Economics
Costs and Cost Analysis
Cholinesterase Inhibitors
Pharmaceutical Preparations
Cost-Benefit Analysis
Dementia
Patient Care
Respite Care
Pharmacology
Economic Models
Long-Term Care
Therapeutics
Life Expectancy
Nursing Homes
Health Care Costs
Caregivers
Uncertainty

Keywords

  • Alzheimer's disease
  • Caregivers
  • Drug therapy
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pharmacoeconomics of Alzheimer's disease. / Dinusson, Jacquelyn; Knopman, David S.

In: Neurologist, Vol. 6, No. 2, 03.2000, p. 116-125.

Research output: Contribution to journalArticle

Dinusson, J & Knopman, DS 2000, 'Pharmacoeconomics of Alzheimer's disease', Neurologist, vol. 6, no. 2, pp. 116-125.
Dinusson, Jacquelyn ; Knopman, David S. / Pharmacoeconomics of Alzheimer's disease. In: Neurologist. 2000 ; Vol. 6, No. 2. pp. 116-125.
@article{209a41555c6647799fb7f9232911a66e,
title = "Pharmacoeconomics of Alzheimer's disease",
abstract = "BACKGROUND - Alzheimer's disease (AD) is the most common form of dementia, comprising an estimated 60 to 80{\%} of the dementing illnesses. As a result of increasing life expectancy and the rising incidence of dementia with advancing age, dementia is a major public health concern. The costs of treatment for AD in the United States rank it among major diseases, but its true costs are not well understood. Pharmacological treatment for AD has been available only in the past 7 years, and much needs to be learned about the current and potential benefits of AD treatment. REVIEW SUMMARY - The costs of caring for patients with AD can be divided into two categories: informal and formal. Informal care is largely provided by family caregivers. The costs associated with informal care involve the time spent in caregiving that constitutes lost opportunities for paid employment. Formal care includes acute medical services as well as day care, respite care, and especially long-term care. These generate what are referred to as formal costs, which are definitely higher for patients with AD than for other comparably aged patients. The introduction of cholinesterase inhibitors to treat AD has raised questions about their economic costs and benefits. Although virtually all clinical trials of anti-AD drugs are of short duration, economic modeling has made it possible to gain some insight into the economic benefits of anti- AD drugs over a longer time period. Four studies that describe economic costs and benefits of anti-AD therapy are reviewed. Because of the uncertainty about the duration and size of clinical effects of cholinesterase inhibitors, the estimates of costs and benefits span a range from cost-saving to expensive. Varying estimates also arise for the impact of anti-AD drugs on formal versus informal costs. If anti-AD therapies were to be shown to reduce formal costs such as nursing home placement, the impact of pharmacological intervention in AD could be dramatic. Economic modeling shows, however, that anti-AD drugs need to reduce informal costs to achieve more sizable economic impact. CONCLUSIONS - Given the efficacy of cholinesterase inhibitors and the current data on the duration of their effects, the estimated economic benefits of this class of drugs are modest. Developing economic models depict what order of magnitude of drug effects are necessary before substantial economic benefits could possibly occur.",
keywords = "Alzheimer's disease, Caregivers, Drug therapy, Pharmacoeconomics",
author = "Jacquelyn Dinusson and Knopman, {David S}",
year = "2000",
month = "3",
language = "English (US)",
volume = "6",
pages = "116--125",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Pharmacoeconomics of Alzheimer's disease

AU - Dinusson, Jacquelyn

AU - Knopman, David S

PY - 2000/3

Y1 - 2000/3

N2 - BACKGROUND - Alzheimer's disease (AD) is the most common form of dementia, comprising an estimated 60 to 80% of the dementing illnesses. As a result of increasing life expectancy and the rising incidence of dementia with advancing age, dementia is a major public health concern. The costs of treatment for AD in the United States rank it among major diseases, but its true costs are not well understood. Pharmacological treatment for AD has been available only in the past 7 years, and much needs to be learned about the current and potential benefits of AD treatment. REVIEW SUMMARY - The costs of caring for patients with AD can be divided into two categories: informal and formal. Informal care is largely provided by family caregivers. The costs associated with informal care involve the time spent in caregiving that constitutes lost opportunities for paid employment. Formal care includes acute medical services as well as day care, respite care, and especially long-term care. These generate what are referred to as formal costs, which are definitely higher for patients with AD than for other comparably aged patients. The introduction of cholinesterase inhibitors to treat AD has raised questions about their economic costs and benefits. Although virtually all clinical trials of anti-AD drugs are of short duration, economic modeling has made it possible to gain some insight into the economic benefits of anti- AD drugs over a longer time period. Four studies that describe economic costs and benefits of anti-AD therapy are reviewed. Because of the uncertainty about the duration and size of clinical effects of cholinesterase inhibitors, the estimates of costs and benefits span a range from cost-saving to expensive. Varying estimates also arise for the impact of anti-AD drugs on formal versus informal costs. If anti-AD therapies were to be shown to reduce formal costs such as nursing home placement, the impact of pharmacological intervention in AD could be dramatic. Economic modeling shows, however, that anti-AD drugs need to reduce informal costs to achieve more sizable economic impact. CONCLUSIONS - Given the efficacy of cholinesterase inhibitors and the current data on the duration of their effects, the estimated economic benefits of this class of drugs are modest. Developing economic models depict what order of magnitude of drug effects are necessary before substantial economic benefits could possibly occur.

AB - BACKGROUND - Alzheimer's disease (AD) is the most common form of dementia, comprising an estimated 60 to 80% of the dementing illnesses. As a result of increasing life expectancy and the rising incidence of dementia with advancing age, dementia is a major public health concern. The costs of treatment for AD in the United States rank it among major diseases, but its true costs are not well understood. Pharmacological treatment for AD has been available only in the past 7 years, and much needs to be learned about the current and potential benefits of AD treatment. REVIEW SUMMARY - The costs of caring for patients with AD can be divided into two categories: informal and formal. Informal care is largely provided by family caregivers. The costs associated with informal care involve the time spent in caregiving that constitutes lost opportunities for paid employment. Formal care includes acute medical services as well as day care, respite care, and especially long-term care. These generate what are referred to as formal costs, which are definitely higher for patients with AD than for other comparably aged patients. The introduction of cholinesterase inhibitors to treat AD has raised questions about their economic costs and benefits. Although virtually all clinical trials of anti-AD drugs are of short duration, economic modeling has made it possible to gain some insight into the economic benefits of anti- AD drugs over a longer time period. Four studies that describe economic costs and benefits of anti-AD therapy are reviewed. Because of the uncertainty about the duration and size of clinical effects of cholinesterase inhibitors, the estimates of costs and benefits span a range from cost-saving to expensive. Varying estimates also arise for the impact of anti-AD drugs on formal versus informal costs. If anti-AD therapies were to be shown to reduce formal costs such as nursing home placement, the impact of pharmacological intervention in AD could be dramatic. Economic modeling shows, however, that anti-AD drugs need to reduce informal costs to achieve more sizable economic impact. CONCLUSIONS - Given the efficacy of cholinesterase inhibitors and the current data on the duration of their effects, the estimated economic benefits of this class of drugs are modest. Developing economic models depict what order of magnitude of drug effects are necessary before substantial economic benefits could possibly occur.

KW - Alzheimer's disease

KW - Caregivers

KW - Drug therapy

KW - Pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=0034027386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034027386&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 116

EP - 125

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 2

ER -